Diabeloop

Focus: Diabeloop is a France-based biotechnology company specializing in artificial pancreas devices for diabetes management, currently in Series C+ funding stage. The company focuses on closed-loop insulin delivery systems targeting both Type 1 and Type 2 diabetes populations.

Gastroenterology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

SERIES C +

Open Jobs

About Diabeloop

AI assessmentNot Hiring

No open roles listed right now. Follow Diabeloop to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

5 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

DBLG1 System

Type1diabetes

N/A

Clinical Trials (1)

NCT04749693Observational Study of the Use of DBLG1 System in Real Life

N/A

Help build intelligence for Diabeloop

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Deep specialization in high-impact diabetes technology with multiple device programs in active clinical development (5 trials across DBLG1, DBL-4pen, and closed-loop systems)
European biotech base in Grenoble with potential for meaningful clinical advancement in artificial pancreas space, a high-unmet-need indication
Series C+ stage offers mid-career growth opportunities before potential exit or commercialization phase

Watch Out For

Zero active job openings currently posted, suggesting limited near-term hiring or potential organizational constraints
No commercial products or revenue reported; career progression depends entirely on clinical and regulatory success of device programs
Limited public financial data and no disclosed funding amounts create uncertainty around cash runway and long-term stability

Generated by Claude from Diabeloop's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Actimetry

Type 2 Diabetes Treated With Insulin

N/A

Clinical Trials (1)

NCT04522882Clinical Data Collection for the Closed Loop Development for the Type 2 Diabetes Treatment - DT2_1

N/A

Use of the device DBL-4pen

Diabetes Mellitus, Type 2

N/A

Clinical Trials (1)

NCT05733962Evaluation of the Efficacy and Safety of DBL-4pen Mobile Application in Patients With Type 2 Diabetes

N/A